Authors
Latest:
A Pricing Revolution: The State OffensiveThe second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.
Latest:
A Roadmap to Pharma ResilienceTo safeguard patient access to life-saving medications, pharma companies must prioritize building robust resilience strategies that encompass IT systems, inventory management, risk mitigation, and regulatory compliance.
Latest:
Reaching the Healthcare Professional After COVID-19Join Pharmaceutical Executive® for an information-packed virtual conference that provides valuable advice to bolster and transform the way you reach HCPs in this time of evolution. Live: Thursday, Aug. 13, 2020 at 8:15AM EDT. On demand available after airing until Aug. 13, 2021.
Latest:
The Evolution of Healthcare Communication: Bridging the HCP-Patient DivideKey trends in healthcare communication to build trust between healthcare providers and their patients.
Latest:
The data you’re missingLatest:
The Personalized Patient Journey: A New Standard of Patient CentricityWebinar Date/Time: Wed, Apr 12, 2023 1:00 PM EDT
Latest:
A Case for Payer Engagement and Participation in Clinical ResearchCollaboration can make commercialization processes efficient and effective.
Latest:
Navigating the CBD Research Landscape: Unveiling Best Practices in the Post-MMCREA EraAlthough research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.
Latest:
Making the Most of the Rising Biopharma M&AsBiopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.
Latest:
FDA Offers GDUFA III InsightThe Generic Drug User Fee Amendments, designed to facilitate the delivery of safe and effective generic drugs to the public and improve the predictability of the ANDA assessment process, has undergone changes that will impact the pre-ANDA and ANDA approval process—and ultimately the path for generic drugs to approval.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Gene Therapy on the Verge of Taking its Next Evolutionary StepThe shift from (ultra) rare to prevalent diseases calls for new vector manufacturing technologies
Latest:
Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A RaceBig pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.
Latest:
Pre-Launch Prep for Emerging Biopharmas: Data First, Then the RestMaking early commercial data and analytics decisions for launch cen future-proof their data management.
Latest:
Animating for Your Audience: The Right Visual for Your Dev StageFrom early-stage funding to commercialization, startups must adapt their strategies and messaging to effectively attract investors, build partnerships, and ultimately succeed.
Latest:
How Pharma is Reinventing Patient EngagementTuesday, October 12, 2021 at 1pm EDT | 10am PDT | 6pm BST We’re at a tipping point: patient engagement is now a key area of focus, and life sciences companies will be able to differentiate by shifting away from traditional models and embracing platforms that uniquely combine high tech with high touch. Join Andrea Heslin Smiley, President and CEO of VMS BioMarketing, the leading provider of patient adherence solutions, for a discussion on how the industry is rapidly transforming how it engages with its end customers.
Latest:
The Global Vaccine R&D Pipeline and Delivery ImplicationsThe current vaccine pipeline brings promise of significant global health advancements—yet development gaps remain, and the future delivery challenges must be considered.
Latest:
How Medical Affairs Can Contribute to Successful Drug LaunchFaster launch planning leads to greater access.
Latest:
Why A New Mix of Field Skills is Crucial to Thriving in the Digital EraEvolving preferences of HCPs during the pandemic have put an emphasis on learning new skillsets for pharma reps.
Latest:
10 Practical Regulatory Questions to Ask During a Marketing Authorization Transfer ProcessWith large M&A deals comes a complex Market Authorization Transfer (MAT) process, during which regulatory teams must weigh several operational aspects while creating a roadmap that takes them into account. Cecile Riboud outlines some key questions that are necessary for planning and executing a successful MAT process.
Latest:
HEOR: From Proving Product Value to Proving Its Own WorthThe recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.
Latest:
Embracing the Future: Meeting Doctors and Patients Where They Are NowPharma companies must embrace the future to advance commercialization.
Latest:
Creating a Digital Solution Patients and HCPs Will UseDeveloping a digital health solution that patients and HCPs will use requires creating technology that addresses unmet needs, integrates with clinical care pathways, and has strong user safeguards, writes Matt Norton.
Latest:
Why Are We Surrendering to COVID?Industry must continue research and development to combat the pandemic.
Latest:
Marketers: Physicians are People FirstUnderstanding the changes in day-to-day life for physicians during COVID and how life science executives can address them.
